Basis: FMP quote market capitalization / four-quarter operating cash flow. Source: stored company filings and market data; unavailable inputs remain N/A.
The Price/OCF ratio is N/A as of 2026-10-06T12:01:28.676Z.
Calculation as of: 2026-10-06T12:01:28.676Z.
Quote observation: 2026-10-05T20:00:01.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 396f74b358d2be52688229160785b883c1ccba5e7e57b4b59ce0869c705c56f9
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PRICE/OCF RATIO
N/A
Market Cap
$416.68M
Price/OCF Ratio
N/A
TTM Avg
21.33
3Y Avg
20.74
5Y Avg
20.74
Market Cap
$410.54M
Price/OCF Ratio
N/A
TTM Avg
6.66
3Y Avg
6.66
5Y Avg
6.66
Market Cap
$408.21M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$428.16M
Price/OCF Ratio
N/A
TTM Avg
250.18
3Y Avg
250.18
5Y Avg
250.18
Market Cap
$447.43M
Price/OCF Ratio
N/A
TTM Avg
15.33
3Y Avg
15.33
5Y Avg
15.33
Market Cap
$450.64M
Price/OCF Ratio
N/A
TTM Avg
3.55
3Y Avg
3.55
5Y Avg
3.55
Market Cap
$453.70M
Price/OCF Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | PRICE/OCF RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Carlsmed, Inc. (CARL) | $415.93M | N/A | N/A | N/A | N/A |
| Arcturus Therapeutics Holdings Inc. (ARCT)vs › | $416.68M | N/A | 21.33 | 20.74 | 20.74 |
| Atea Pharmaceuticals, Inc. (AVIR)vs › | $410.54M | N/A | 6.66 | 6.66 | 6.66 |
| Eikon Therapeutics, Inc. Common Stock (EIKN)vs › | $408.21M | N/A | N/A | N/A | N/A |
| Shoulder Innovations, Inc. (SI)vs › | $406.47M | N/A | N/A | N/A | N/A |
| Editas Medicine, Inc. (EDIT)vs › | $428.16M | N/A | 250.18 | 250.18 | 250.18 |
| Capricor Therapeutics, Inc. (CAPR)vs › | $447.43M | N/A | 15.33 | 15.33 | 15.33 |
| Assembly Biosciences, Inc. (ASMB)vs › | $450.64M | N/A | 3.55 | 3.55 | 3.55 |
| DiaMedica Therapeutics Inc. (DMAC)vs › | $453.70M | N/A | N/A | N/A | N/A |
| Canopy Growth Corporation (CGC)vs › | $373.40M | N/A | N/A | N/A | N/A |
P/OCF Ratio
N/A
P/FCF Ratio
N/A
P/OCF measures market price relative to operating cash flow: market cap divided by TTM operating cash flow. OCF is cash from operations before capital expenditures, so it sits above free cash flow — P/OCF typically reads below P/FCF, with the widest gap for capex-heavy businesses.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
